^
No biomarker
Neuroblastoma
dinutuximab beta
Sensitive: A1 - Approval
No biomarker
Neuroblastoma
doxorubicin hydrochloride
Sensitive: A1 - Approval
No biomarker
Neuroblastoma
melphalan
Sensitive: A1 - Approval
No biomarker
Neuroblastoma
dinutuximab
Sensitive: A1 - Approval
No biomarker
Neuroblastoma
cyclophosphamide oral
Sensitive: A1 - Approval
No biomarker
Neuroblastoma
naxitamab
Sensitive: A1 - Approval
ALK positive
Neuroblastoma
crizotinib
Sensitive: C3 – Early Trials
ALK R1275Q
Neuroblastoma
crizotinib
Sensitive: C3 – Early Trials
ATRX mutation
Neuroblastoma
AZD1775
Sensitive: C3 – Early Trials
ALK rearrangement + ALK R1275Q + TP53 mutation
Neuroblastoma
crizotinib
Resistant: C4 – Case Studies
PGBD5 overexpression
Neuroblastoma
cisplatin
Sensitive: D – Preclinical
PGBD5 overexpression
Neuroblastoma
AZD6738
Sensitive: D – Preclinical
PGBD5 underexpression
Neuroblastoma
AZD6738
Sensitive: D – Preclinical
ALK R1275Q
Neuroblastoma
TAE-684
Resistant: D – Preclinical
MYCN amplification
Neuroblastoma
GSK2816126 + MTX110
Sensitive: D – Preclinical
MYCN amplification
Neuroblastoma
OTX015
Sensitive: D – Preclinical
MYCN amplification
Neuroblastoma
JQ-1 + MTX110
Sensitive: D – Preclinical
MYCN amplification
Neuroblastoma
brigatinib
Resistant: D – Preclinical
MYCN amplification
Neuroblastoma
crizotinib
Resistant: D – Preclinical
ALK F1174L
Neuroblastoma
crizotinib
Resistant: D – Preclinical
ALK F1174L
Neuroblastoma
AZD3463
Sensitive: D – Preclinical
ALK F1174L
Neuroblastoma
alectinib
Sensitive: D – Preclinical
ALK amplification
Neuroblastoma
alectinib
Sensitive: D – Preclinical
ALK F1245C
Neuroblastoma
lorlatinib
Sensitive: D – Preclinical
ALK F1174C
Neuroblastoma
lorlatinib
Sensitive: D – Preclinical
ALK F1174L
Neuroblastoma
TAE-684
Sensitive: D – Preclinical
MYCN amplification + ALK rearrangement
Neuroblastoma
brigatinib
Sensitive: D – Preclinical
MYCN amplification + ALK F1174V
Neuroblastoma
brigatinib
Sensitive: D – Preclinical
MYCN amplification + ALK F1174V
Neuroblastoma
crizotinib
Sensitive: D – Preclinical
NF1 underexpression
Neuroblastoma
binimetinib
Sensitive: D – Preclinical
MYCN amplification + ALK F1174L
Neuroblastoma
lorlatinib
Sensitive: D – Preclinical
ALK D1091N
Neuroblastoma
AZD3463
Sensitive: D – Preclinical
MYCN amplification + ALK rearrangement
Neuroblastoma
crizotinib
Sensitive: D – Preclinical
MYCN amplification + ALK R1275Q
Neuroblastoma
lorlatinib
Sensitive: D – Preclinical
ETV6-NTRK3 fusion
Neuroblastoma
TPX-0005
Sensitive: D – Preclinical
CD276 expression
Neuroblastoma
B7-H3-targeted antibody-drug conjugate
Sensitive: D – Preclinical
TERT rearrangement
Neuroblastoma
OTX015
Sensitive: D – Preclinical
ALK positive
Neuroblastoma
CAR-T immunotherapy
Sensitive: D – Preclinical
NRAS Q61K
Neuroblastoma
ASN007
Sensitive: D – Preclinical
MYCN amplification
Neuroblastoma
DHODH inhibitor
Sensitive: D – Preclinical
MYCN amplification
Neuroblastoma
olaparib + MK-8776
Sensitive: D – Preclinical